Our vision is to be a "group that will continue to create the solutions needed by people and the earth" under our corporate philosophy "Jun-Ri-Soku-Yu" (adhering to reason leads to prosperity).
The core technologies supporting the Toyobo Group’s growth can be categorized into four areas: polymerization, modification, processing, and biotechnology. Over the years, we have generated a range of new products by combining and integrating these technologies.
Going forward, we will meet market demand for "Products & Experience" (create customer value by providing products, services and solutions) and social demands (SDGs, etc.), and "Manufacture" technology for demand (providing optimal value throughout the value chain, in terms of quality, cost, and lead time).
In order to further promote this initiative, we have formulated the Social Bond Framework. Through the issuance of Social Bonds, we actively disclose to stakeholders including investors, customers, suppliers, local communities and employees about value creation activities related to the Toyobo Group’s sustainability activities, ongoing activities, CSV and SDGs. We incorporate constructive dialogue into our business activities and then aim for sustainable growth and expansion of stakeholders by ensuring a continued mutually prosperous relationship between our future business and stakeholders.
Name of the bonds |
Toyobo Co., Ltd. 43th unsecured straight bonds (with limited inter-bond pari passu clause) (Social Bonds) |
---|
Issuance amount |
10.0 billion yen |
---|
Issuance period |
7 years |
---|
Interest rate |
0.250% |
---|
Condition determination date |
December 1, 2021 |
---|
Paid-in date |
December 7, 2021 |
---|
Maturity date |
December 7, 2028 |
---|
Acquired rating |
Japan Credit Rating Agency, Ltd. / A |
---|
Outline of use of proceeds and consistency with SDGs |
Expences relating to medical membrane production (CAPEX and R&D expences of medical membranes such as artificial kidney hollow fiber, virus removing membranes, etc.)
Expences relating to reagents production (CAPEX and R&D expences of raw materials, etc. for diagnostic reagents, reagents for genetic testing, etc.) |
---|
Lead managers |
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. Nomura Securities Co., Ltd. Mizuho Securities Co., Ltd. |
---|
Structuring Agent* |
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. |
---|
*Entities that provide support for the implementation of Social Bonds through advice, etc. regarding the formulation of the framework and on obtaining external third-party evaluations.
The Social Bond Framework was formulated in accordance with the Social Bond Principles 2021 (the International Capital Market Association, ICMA) and the Social Bond Guidelines (set by the Financial Services Agency on October 2021) in order to issue Social Bonds.
We obtained a third party opinion from the independent external institution Rating and Investment Information, Inc. (R&I) regarding confirmation with the Social Bond Principles 2021 (ICMA) and the Social Bond Guidelines (set by the Financial Services Agency on October 2021).
For details, please refer to R&I's website (in Japanse only).
Please see the following investors that have announced their investments in the Social Bonds (As of December 7, 2021 / in the order of Japanese syllabary)
Ishikawa Credit Federations of Agricultural Cooperatives
Ibaraki Prefectural Credit Federations of Agricultural Cooperatives
Ome Shinkin Bank
OGAKISEINO SHINKIN BANK
Osaka Shoko Shinkin Bank
The Kita Osaka Shinkin Bank
The 77 Bank, Ltd.
SHINONOME SHINKIN BANK
Shinkin Central Bank
Suwa Shinkin Bank
The Seiwa Credit Cooperative
SAISON AUTOMOBILE&FIRE INSURANCE CO.,LTD
THE DAIDO FIRE AND MARINE INSURANCE CO., LTD.
Daitokyo Shinkumi Credit Cooperative
Tokyo City Shinkin Bank
The First Bank of Toyama,Ltd.
NAGANO SHINKIN BANK
HAMAMATSU IWATA SHINKIN BANK
HANDA SHINKIN BANK
BlackRock Japan Co., Ltd.
Mie Prefecture credit federation of agricultural cooperatives
MIYAZAKI DAIICHI SHINKIN BANK
MEIJO UNIVERSITY
The Yamanashi Chuo Bank, Ltd.
LIFENET INSURANCE COMPANY
The allocation reporting and the impact reporting will be reported anually (in early December) on Toyobo's website.
1. Allocation reporting
Procurement Amount (Amount excluding expences of the issuance from issuance amount of the bonds)
9,940 million yen
Proceeds Allocated
Eligible projects | |
Expences relating to medical membrane production | 5,040 |
Expences relating to reagents production | 4,900 |
9,940 million yen |
Proceeds Unallocated
0 million yen
2. Impact reporting
Eligible projects | Outcome | Impact |
Expences relating to medical membrane production |
Production plants were constructed and in preparation for operation | |
Expences relating to reagents production |
- Production capacity: Approx. 1.5-fold increase compared to FY 3/20 - Started operation and production from April 2024 Started full-fledged production from July and sales from August 2024
|
Maintained global medical systems Contribution to clinical biochemistry |
Reporting is reviewed by R&I.